Areas of Focus

Fibrocor Therapeutics is advancing precision therapies for kidney diseases driven by fibrosis. Our work centers on conditions where tissue scarring leads to progressive loss of kidney function and limited treatment options. By studying human kidney samples directly, we aim to identify disease-specific pathways and develop targeted therapies that slow or prevent fibrotic injury.

Kidney Allograft Fibrosis

Progressive complication of kidney transplantation driven by ongoing immune-mediated and non-immune injury to the transplanted kidney. Over time, these repeated injuries trigger abnormal wound-healing responses that lead to interstitial fibrosis and tubular atrophy (IF/TA), with gradual loss of functioning kidney tissue. This process is a major cause of chronic allograft dysfunction and late graft failure, often forcing patients back onto dialysis or requiring a repeat transplant.

What it is
Kidney allograft fibrosis is a chronic, progressive scarring process that affects a transplanted kidney over time. It results from repeated immune and non-immune injury to the graft, leading to interstitial fibrosis and tubular atrophy (IF/TA). As healthy tissue is replaced by scar, overall kidney function declines and the risk of late graft failure rises.

How it presents
Kidney allograft fibrosis is often silent early on and detected through routine monitoring rather than symptoms. Key features include slowly rising creatinine, declining eGFR, and increasing proteinuria. Biopsy typically shows interstitial fibrosis, tubular atrophy, and varying degrees of inflammation or vascular injury, reflecting both chronic immune-mediated damage and other insults such as ischemia, drug toxicity, or infection.

Current care
Standard management focuses on controlling the drivers of injury rather than fibrosis itself. This includes optimization of immunosuppression to prevent rejection, strict blood pressure control, management of proteinuria (e.g., ACE inhibitors or ARBs), minimization of calcineurin inhibitor toxicity, and aggressive treatment of infections and other comorbidities. Despite these measures, many patients experience progressive graft dysfunction that can ultimately lead back to dialysis or the need for re-transplantation.

Unmet need
There are no approved therapies that specifically and directly target the fibrotic pathways in the transplanted kidney. As a result, clinicians can slow but not stop the progression of scarring, and patients remain at high risk for graft loss over time.

Fibrocor’s focus
Fibrocor is using patient-derived kidney allograft tissue and translational models to identify and target the molecular drivers of fibrosis in transplanted kidneys. The goal is to develop anti-fibrotic, disease-modifying therapies that intervene earlier in the process, preserve graft function for longer, and reduce the likelihood that patients will lose their transplant.

A rare inherited kidney disease caused by mutations in type IV collagen genes (COL4A3–5). It leads to progressive kidney scarring, hearing loss, and eye changes. Current treatments slow the decline but don’t address the underlying fibrosis.

Alport Syndrome

What it is
Alport syndrome is a rare inherited kidney disease caused by variants in the COL4A3, COL4A4, or COL4A5 genes. These genes code for type IV collagen, an essential part of the glomerular basement membrane in the kidney. Damage to this structure leads to progressive kidney scarring. The condition can be X-linked, autosomal recessive, or autosomal dominant, which affects the rate and severity of progression.

How it presents
Early signs include persistent blood in the urine and, over time, increasing proteinuria and kidney function decline. Many patients also develop hearing loss and characteristic eye changes.

Current care
Treatment focuses on slowing progression and protecting kidney function. Blood pressure control and blockade of the renin–angiotensin system (ACE inhibitors or ARBs) are standard. For adults with chronic kidney disease and proteinuria, SGLT2 inhibitors may provide additional benefit. When kidney failure occurs, transplant remains the best option, though outcomes vary based on genetics and sex.

Unmet need
No approved therapies directly address the underlying fibrotic process in Alport syndrome. Patients continue to face limited options before kidney failure develops.

Fibrocor’s focus
Fibrocor is using patient-derived kidney tissue to uncover and target molecular drivers of fibrosis in Alport syndrome. Our goal is to develop therapies that intervene earlier in disease progression and reduce scarring in the kidney.

Chronic Kidney Disease

A common, progressive condition marked by persistent kidney damage or reduced function. Newer medicines can slow decline, but many patients remain undiagnosed or continue to progress, highlighting the need for treatments that directly address kidney fibrosis.

What it is
CKD is an umbrella term for abnormalities of kidney structure or function that persist for at least three months. It can result from diabetes, high blood pressure, immune disease, inherited disorders, toxins, or repeated kidney injury. CKD is classified by its cause, estimated glomerular filtration rate (eGFR), and urine albumin level.

How it presents
Early CKD is often silent and usually detected through a low eGFR, increased urine albumin, or structural changes on imaging. As disease advances, patients may develop swelling, fatigue, itching, nausea, poor appetite, or changes in urination. Complications include anemia, electrolyte and bone disorders, cardiovascular disease, and kidney failure.

Current care
Treatment depends on the cause and stage. Core management includes blood pressure control, ACE inhibitor or ARB therapy for albuminuric CKD, and SGLT2 inhibitors for eligible patients. Selected people with type 2 diabetes may also receive finerenone or a GLP-1 receptor agonist. Care also addresses anemia, acidosis, and mineral-bone disease. Advanced kidney failure may require dialysis or transplantation.

Unmet need
Current therapies can delay progression, but they do not reliably stop kidney function loss, and many patients retain substantial risk of cardiovascular events and kidney failure. Because CKD arises from many causes and biological pathways, treatment response is uneven. Therapies that safely interrupt fibroblast activation and scar formation could preserve functioning tissue across multiple CKD types.

Fibrocor’s focus
Fibrocor uses patient-derived kidney tissue, biopsy transcriptomics, and linked clinical data to identify molecular drivers of fibroblast activation and excessive collagen deposition. Its current kidney programs focus on Kidney allograft fibrosis and Alport Syndrome with the broader aim of applying validated anti-fibrotic targets and biomarkers to additional forms of CKD